154 related articles for article (PubMed ID: 37442024)
1. Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Shafa A; Watkins AB; McGree ME; Weroha SJ; Wahner Hendrickson AE; Block MS; Langstraat CL; McBane RD; Bakkum-Gamez JN; Kumar A
Gynecol Oncol; 2023 Sep; 176():36-42. PubMed ID: 37442024
[TBL] [Abstract][Full Text] [Related]
2. Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea.
Shin W; Lee S; Lim MC; Jung J; Kim HJ; Cho H
Cancer Med; 2021 Mar; 10(6):2045-2053. PubMed ID: 33638309
[TBL] [Abstract][Full Text] [Related]
3. Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer.
Chavan DM; Huang Z; Song K; Parimi LRH; Yang XS; Zhang X; Liu P; Jiang J; Zhang Y; Kong B; Li L
Medicine (Baltimore); 2017 Oct; 96(42):e7935. PubMed ID: 29049188
[TBL] [Abstract][Full Text] [Related]
4. Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer.
Chokshi SK; Gaughan JP; Krill L
J Thromb Thrombolysis; 2022 Jan; 53(1):202-207. PubMed ID: 34185227
[TBL] [Abstract][Full Text] [Related]
5. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
6. Venous Thromboembolism in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian Cancer and Impact on Survival.
Black KA; Ghosh S; Singh N; Chu P; Pin S
J Obstet Gynaecol Can; 2021 Dec; 43(12):1380-1387. PubMed ID: 34087490
[TBL] [Abstract][Full Text] [Related]
7. Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Moufarrij S; Sassine D; Basaran D; Jewell EL
Gynecol Oncol; 2023 Mar; 170():167-171. PubMed ID: 36701837
[TBL] [Abstract][Full Text] [Related]
8. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Salinaro JR; McQuillen K; Stemple M; Boccaccio R; Ehrisman J; Lorenzo AM; Havrilesky L; Secord AA; Galvan Turner V; Moore KN; Davidson B
Int J Gynecol Cancer; 2020 Apr; 30(4):491-497. PubMed ID: 32054646
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
Xu Y; Jia Y; Zhang Q; Du Y; He Y; Zheng A
Gynecol Oncol; 2021 Feb; 160(2):610-618. PubMed ID: 33221022
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Basaran D; Boerner T; Suhner J; Sassine D; Liu Y; Grisham RN; Tew WP; Gardner GJ; Zivanovic O; Sonoda Y; Long Roche K; Chi DS; Abu-Rustum NR; Soff GA; Jewell EL
Gynecol Oncol; 2021 Oct; 163(1):36-40. PubMed ID: 34312001
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
Garas SN; McAlpine K; Ross J; Carrier M; Bossé D; Yachnin D; Mallick R; Cagiannos I; Morash C; Breau RH; Lavallée LT
Urol Oncol; 2022 Aug; 40(8):381.e1-381.e7. PubMed ID: 35581123
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
13. Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
McLaughlin HD; Greco P; Straubhar AM; Rolston A; McCool K; Brackmann M; Siedel JH; McLean K; Reynolds RK; Uppal S
Gynecol Oncol; 2023 Nov; 178():89-95. PubMed ID: 37832182
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
15. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study.
Oxley SG; Achampong YA; Sambandan N; Hughes DJ; Thomas M; Lockley M; Olaitan A
Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2091-2096. PubMed ID: 34486103
[TBL] [Abstract][Full Text] [Related]
17. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
18. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.
Yang SP; Chen JX; Xu JY; Lei J; Wu SG; Zhou J
Cancer Med; 2022 Jul; 11(14):2836-2845. PubMed ID: 35274489
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis.
Wiegers HMG; Schaafsma M; Guman NAM; Zelisse HS; Mulder FI; Middeldorp S; van Es N; Mom CH
J Thromb Haemost; 2023 Feb; 21(2):294-302. PubMed ID: 36700503
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.
Greco PS; Bazzi AA; McLean K; Reynolds RK; Spencer RJ; Johnston CM; Liu JR; Uppal S
Obstet Gynecol; 2017 Jun; 129(6):979-985. PubMed ID: 28486358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
